Table 3.
Outcomes in completers stratified by visual acuity at presentation.
| Visual acuity ≥69 letters (20/40 or better) | Visual acuity ≤68 letters (20/50 or worse) | |
|---|---|---|
| Eyes, n | 130 | 79 |
| Patients, na | 110 | 63 |
| Baseline VA letters, mean (SD) | 75.8 (5.1) | 54.9 (15.5) |
| Final VA letters, mean (SD) | 75.6 (5.8) | 63.6 (13.5) |
| Change VA letters, mean (95% CI) | −0.2 (−1.3, 0.9) | 8.7 (4.7, 12.6) |
| Gain ≥ 10 letters % | 9 | 43 |
| Loss ≥ 10 letters % | 10 | 8 |
| VA ≥ 69 letters %, baseline/final | 100/89 | 0/44 |
| VA ≤ 35 letters %, baseline/final | 0/0 | 11/5 |
| Baseline CST µm, mean (SD) | 384 (83) | 441 (129) |
| Final CST µm, mean (SD) | 358 (86) | 386 (119) |
| Change CST µm, mean (95% CI) | −25 (−38, −13) | −52 (−84, −21) |
| Injectionsb, median (Q1, Q3) | 6 (4, 9) | 7 (4, 9) |
| Additional laser, n | 18 | 3 |
| Visits, median (Q1, Q3) | 8 (6, 12) | 9 (6, 10) |
‘Completers’—eyes with 12 months of observation from the start of treatment
n number, VA visual acuity, SD standard deviation, CI confidence interval, CST central subfield thickness, Q1 first quantile, Q3 third quantile.
aPatients with each eye in two groups are repeated.
bNumber of bevacizumab injections.